Shares are dropping after the big biotech says it's scrapping an R&D program for ALS. But a new pill for multiple sclerosis continues to be the major catalyst for this stock.
Biogen Idec, Pfizer, Bristol-Myers and Celgene are among companies awaiting US approval of key treatments.
The market is growing and the opportunities are there, but so are the risks.
The company's forecast for its pipeline has doubled in the last year.
Some pharma stocks could get a shot in the arm as CDC issues early warning.
Teva is downgraded to 'market perform,' and Under Armour is initiated with an 'underweight.'
10 of the Continent's best exchange-traded funds for the new year.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.